Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 5 records in total 5
    records per page




    A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19

    Authors: Yadi Zhou; Yuan Hou; Jiayu Shen; Asha Kalianpur; Joe Zein; Daniel A. Culver; Samar Farha; Suzy Comhair; Claudio Fiocchi; Michaela U. Gack; Reena Mehra; Thaddeus S Stappenbeck; Timothy Chan; Charis Eng; Jae U. Jung; Lara Jehi; Serpil Erzurum; Feixiong Cheng

    doi:10.26434/chemrxiv.12579137.v1 Date: 2020-07-02 Source: ChemRxiv

    The global Coronavirus Disease MESHD 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has led to unprecedented social and economic consequences. The risk of morbidity and mortality due to COVID-19 increases dramatically in the presence of co-existing medical conditions while the underlying mechanisms remain unclear. Furthermore, there are no proven effective therapies for COVID-19. This study aims to identify SARS-CoV-2 pathogenesis, diseases manifestations, and COVID-19 therapies using network medicine methodologies along with clinical and multi-omics observations. We incorporate SARS-CoV-2 virus-host protein-protein interactions, transcriptomics, and proteomics into the human interactome. Network proximity measure revealed underlying pathogenesis for broad COVID-19-associated manifestations. Multi-modal analyses of single-cell RNA-sequencing data showed that co-expression of ACE2 and TMPRSS2 was elevated in absorptive enterocytes from the inflamed ileal tissues of Crohn's disease HP Crohn's disease MESHD patients compared to uninflamed tissues, revealing shared pathobiology by COVID-19 and inflammatory bowel disease MESHD. Integrative analyses of metabolomics and transcriptomics (bulk and single-cell) data from asthma HP asthma MESHD patients indicated that COVID-19 shared intermediate inflammatory endophenotypes with asthma HP asthma MESHD (includingIRAK3 and ADRB2). To prioritize potential treatment, we combined network-based prediction and propensity score (PS) matching observational study of 18,118 patients from a COVID-19 registry. We identified that melatonin (odds ratio (OR) = 0.36, 95% confidence interval (CI) 0.22-0.59) was associated with 64% reduced likelihood of a positive laboratory test result for SARS-CoV-2. Using PS-matching user active comparator design, melatonin was associated with 54% reduced likelihood of SARS-CoV-2 positive test result compared to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (OR = 0.46, 95% CI 0.24-0.86).

    Intestinal inflammation MESHD modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

    Authors: Mayte Suárez-Fariñas; Minami Tokuyama; Gabrielle Wei; Ruiqi Huang; Alexandra Livanos; Divya Jha; Anais Levescot; Roman Kosoy; Haritz Irizar; Wenhui Wang; Ryan Ungaro; Antonio Di Narzo; Gustavo Martinez; Maria Suprun; Michael J Corley; Aleksandar Stojmirovic; Sander Houten; Mark Curran; Carrie Brodmerkel; Jacqueline Perrigoue; Joshua R Friedman; Ke Hao; Eric E Schadt; Jun Zhu; Huaibin M Ko; Judy Cho; Marla C Dubinsky; Bruce E Sands; Lishomwa Ndhlovu; Nadine Cerf-Bensusan; Andrew Kasarskis; Jean-Frederic Colombel; Noam Harpaz; Carmen Argmann; Saurabh Mehandru

    doi:10.1101/2020.05.21.109124 Date: 2020-05-23 Source: bioRxiv

    Immune dysregulation HP dysregulation MESHD and cytokine release syndrome have emerged as pathological hallmarks of severe Coronavirus Disease MESHD 2019 (COVID-19), leading to the evaluation of cytokine antagonists as therapeutic agents. A number of immune-directed therapies being considered for COVID-19 patients are already in clinical use in chronic inflammatory conditions like inflammatory bowel disease MESHD ( IBD MESHD). These considerations led us to systematically examine the intersections between COVID-19 and the GI MESHD tract during health and intestinal inflammation MESHD. We have observed that IBD MESHD medications, both biologic and non-biologic, do not significantly impact ACE2 and TMPRSS2 expression in the uninflamed intestines. Additionally, by comparing SARS CoV2-induced epithelial gene signatures with IBD MESHD-associated genes, we have identified a shared molecular subnetwork between COVID-19 and IBD MESHD. These data generate a novel appreciation of the confluence of COVID-19- and IBD MESHD-associated inflammation MESHD and provide mechanistic insights supporting further investigation of specific IBD MESHD drugs in the treatment of COVID-19.

    COVID-19 and Inflammatory Bowel Diseases: risk assessment, shared molecular pathways and therapeutic challenges

    Authors: Iolanda Valentina Popa; Mircea Diculescu; Catalina Mihai; Cristina Cijevschi-Prelipcean; Alexandru Burlacu

    doi:10.1101/2020.04.28.20082859 Date: 2020-05-01 Source: medRxiv

    Background. The novel coronavirus SARS-CoV-2 causing COVID-19 disease is yielding a global outbreak with serious threats to public health. In this paper, we aimed to review the current knowledge about COVID-19 infectious risk status in inflammatory bowel disease MESHD ( IBD MESHD) patients requiring immunosuppressive medication. Also, we focused on several molecular insights that could explain why IBD MESHD patients appear to not have higher risks of infection TRANS risks of infection TRANS infection MESHD and worse outcome in COVID-19 than the general population, in attempt to provide scientific support for safer decisions in IBD MESHD patient care. Methods. PubMed electronic database was interogated for relevant articles involving data about common molecular pathways and shared treatment strategies between SARS-CoV-2, SARS-CoV-1, MERS-CoV and inflammatory bowel diseases MESHD. In addition, Neural Covidex, an artificial intelligence tool, was used to answer queries about pathogenic coronaviruses and possible IBD MESHD interactions using the COVID-19 Open Research Dataset (CORD-19). Discussions. Few molecular and therapeutic interactions between IBD MESHD and pathogenic coronaviruses were explored. First, we showed how the activity of soluble angiotensin-converting enzyme 2, CD209L alternate receptor and phosphorylated subunit of eukaryotic translation initiation factor 2 might exert protective impact in IBD MESHD in case of coronavirus infection MESHD. Second, IBD MESHD medication was discussed in the context of possible beneficial effects on COVID-19 pathogeny including "cytokine storm" prevention and treatment, immunomodulation, interferon signaling blocking, viral endocytosis inhibition. Conclusions. Using current understanding of SARS-CoV-2 as well as other pathogenic coronaviruses immunopathology, we showed why IBD MESHD patients should not be considered at an increased risk of infection TRANS risk of infection TRANS infection MESHD or more severe outcomes. Whether our findings are entirely applicable to the pathogenesis, disease susceptibility and treatment management of SARS-CoV-2 infection MESHD in IBD MESHD must be further explored.

    Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation MESHD, more severe disease, and response to anti-TNF therapy in Crohn's disease HP Crohn's disease MESHD

    Authors: Alka A Potdar; Shishir Dube; Takeo Naito; Gregory Botwin; Talin Haritunians; Dalin Li; Shaohong Yang; Janine Bilsborough; Lee A Denson; Mark Daly; Stephan R Targan; Phillip Fleshner; Jonathan Braun; Subra Kugathasan; Thaddeus S Stappenbeck; Dermot P B McGovern

    doi:10.1101/2020.04.19.20070995 Date: 2020-04-23 Source: medRxiv

    Angiotensin-Converting Enzyme 2 (ACE2) has been identified as the host receptor for SARS-coronavirus MESHD 2 (SARS-CoV-2) which has infected millions world-wide and likely caused hundreds of thousands of deaths. Utilizing transcriptomic data from four cohorts taken from Crohn's disease HP Crohn's disease MESHD ( CD MESHD) and non-inflammatory bowel disease MESHD ( IBD MESHD) subjects, we observed evidence of increased ACE2 mRNA in ileum with demographic features that have been associated with poor outcomes in COVID-19 including age TRANS and raised BMI. ACE2 was downregulated in CD MESHD compared to controls in independent cohorts. Within CD MESHD, ACE2 expression was reduced in inflamed ileal tissue and also remarkably, from uninvolved tissue in patients with a worse prognosis in both adult TRANS and pediatric cohorts. In active CD MESHD, small bowel ACE2 expression was restored by anti-TNF therapy particularly in anti-TNF responders. Collectively our data suggest that ACE2 downregulation is associated with inflammation MESHD and worse outcomes in CD MESHD.

    Questionnaire assessment helps the self-management of patients with inflammatory bowel disease MESHD during the outbreak of Coronavirus Disease MESHD 2019

    Authors: Meiping Yu; Zhenghao Ye; Yu Chen; Tingting Qin; Jiguang Kou; Dean Tian; Fang Xiao

    doi:10.1101/2020.03.25.20043364 Date: 2020-03-27 Source: medRxiv

    Background and Aims: The outbreak of Coronavirus Disease MESHD 2019 (COVID-19) may affect the disease status of patients with inflammatory bowel disease MESHD ( IBD MESHD). This study aimed to assess the disease status of IBD MESHD patients in Hubei province by questionnaire online and guide to the self-management of IBD MESHD patients during this epidemic. Methods: A questionnaire was designed containing the Harvey-Bradshaw Index (HBI), the Partial Mayo Score (PMS), the short inflammatory bowel disease MESHD questionnaire (SIBDQ) and distributed to Hubei IBD MESHD patients online within one month of traffic control after the outbreak of COVID-19. This questionnaire also included some questions about patients' self-report disease conditions and their epidemiological history of COVID-19. Results: A total of 102 eligible questionnaires were included in the analysis. No patient reported infection with severe HP infection with severe MESHD acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) in our study. Our result showed that 69.64% of patients with ulcerative colitis HP ulcerative colitis MESHD ( UC MESHD) and 80.44% of patients with Crohn's disease HP Crohn's disease MESHD ( CD MESHD) were in remission. There was not a statistically significant difference in the proportion of the active disease stage between the two types of disease (p=0.103). The majority of patients (85.29%) had a good health-related quality of life (HRQoL) (SIBDQ[≥]50). The reduction in physical exercise is a risk factor for worsening in conditions (OR=17.593, 95%CI 2.035 to 152.097, p=0.009). Conclusions: The outbreak of COVID-19 might not have a significant impact on most Hubei IBD MESHD patients within one month after the traffic control. The patient's disease condition could be assessed by our questionnaires. Doctors utilized the information and advised for IBD MESHD patients about self-management during the period of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.